Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues

Edward M Wolin,1 Barbara Jarzab,2 Barbro Eriksson,3 Thomas Walter,4 Christos Toumpanakis,5 Michael A Morse,6 Paola Tomassetti,7 Matthias M Weber,8 David R Fogelman,9 John Ramage,10 Donald Poon,11 Brian Gadbaw,12 Jiang Li,12 Janice L Pasieka,13 Abakar Mahamat,14 Fredrik Swahn,15 John Newell-Price,16...

Full description

Bibliographic Details
Main Authors: Wolin EM, Jarzab B, Eriksson B, Walter T, Toumpanakis C, Morse MA, Tomassetti P, Weber MM, Fogelman DR, Ramage J, Poon D, Gadbaw B, Li J, Pasieka JL, Mahamat A, Swahn F, Newell-Price J, Mansoor W, Öberg K
Format: Article
Language:English
Published: Dove Medical Press 2015-09-01
Series:Drug Design, Development and Therapy
Online Access:https://www.dovepress.com/phase-iii-study-of-pasireotide-long-acting-release-in-patients-with-me-peer-reviewed-article-DDDT

Internet

https://www.dovepress.com/phase-iii-study-of-pasireotide-long-acting-release-in-patients-with-me-peer-reviewed-article-DDDT

Similar Items